← Eichor
Study identifier: NCT05665920 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy

Condition: Malignant Breast Neoplasm  ·  Sponsor: Instituto Brasileiro de Controle do Cancer

PhaseNA
Planned participants36
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The reduction in the number of fractions in radiotherapy is especially attractive in several senses, and even more so considering breast cancer, which has a high incidence and generally favorable prognosis. Thus, as a reference Institution, the investigators intend to start the treatment of selected patients with a radiotherapy scheme of 26 Gy / 5 fractions in one week, in a controlled manner, through this project.The investigators consider the moment extremely propitious to start the study, as in addition to having the first publication of a large randomized study, proving the effectiveness and safety of the strategy, the investigators will be able to benefit more patients and the health system itself by minimizing the daily visits of these patients at the hospital.

This description comes directly from the study's public registry record.

Talk to the study team

Eduardo Barbieri  ·  +551198639-1945  ·  edurxt@gmail.com

Alayne Yamada, PhD  ·  +55114450-0347  ·  alayne.yamada@hospitalsaocamilosp.org.br

Always discuss trial participation with your own doctor first.

Locations (1)

IBCC OncologiaSão Paulo, São Paulo, BrazilRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05665920